A Phase 2 interventional study of placebo and Omega-3 carboxylic acids in T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin), sponsored by AstraZeneca. Completed at 5 sites in Sweden. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-17.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing dapagliflozin in Non-alcoholic Fatty Liver Disease — none open to participants now, 2 under way, none of them phase 3. dapagliflozin · Non-alcoholic Fatty Liver Disease.
Among the 10 studies testing dapagliflozin in Non-alcoholic Fatty Liver Disease, this one has the largest enrollment, is the only one that started in 2015, is one of 2 in phase 2, and was the 1st registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 10 studies testing dapagliflozin in Non-alcoholic Fatty Liver Disease is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2015; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 104 across the 10 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca: none open now, 1 under way, none of them phase 3. Of 18 finished, 7 (39%) have results posted.
Among the 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2015, is one of 6 in phase 2, and was the 3rd registered.
AstraZeneca’s Non-alcoholic Fatty Liver Disease studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing dapagliflozin in Non-alcoholic Fatty Liver Disease, from their registry updates:
Among AstraZeneca’s 19 in Non-alcoholic Fatty Liver Disease:
This tab as a report to print or save as PDF → With an account.
This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in up to 5 centres in Sweden to assess the effect of Omega-3 carboxylic acids and dapagliflozin on liver fat in patients with Type 2 diabetes with fatty liver (>5.5% as measured with magnetic resonance imaging (MRI))
Inclusion Criteria: Provision of prior to any study specific procedures; Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated venepuncture; Have liver fat content as assessed by MRI >5.5%; Diagnosis of Type 2 diabetes since at least 6 months in accordance with WHO criteria.
Exclusion Criteria: Any condition when MRI is such as, but not limited to, having a pacemaker or claustrophobia; Diagnosis or signs of Type 1 diabetes (e.g. history of positive islet antibodies); \<60 mL/min at screening (Cockcroft-Gault formula).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo
Drug: Omega-3 carboxylic acids
Drug: Dapagliflozin
Drug: Omega-3 carboxylic acids · Drug: Dapagliflozin
Placebo matching to Omega-3 carboxylic acids (olive oil)
4 g administered as 4 x 1 g capsules
10 mg administered as 10 mg tablet
Placebo matching to dapagliflozin 10 mg
Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo)
To evaluate the efficacy of the combination therapy (Epanova + Dapagliflozin) when compared to placebo with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded treatment. Treatment effect in liver fat reduction (%) was assessed using a mixed linear model with the change from baseline on logarithmic scale as response variable and the logarithm of the baseline value as covariate, treatment as fixed effect, and center as random effect. The treatment effect was then back-transformed to original scale as Geometric mean ratio and presented as percentage change from baseline.
Time frame: 12 weeks
Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups)
To evaluate the relative efficacy of the combination of Epanova and dapagliflozin versus Epanova alone and dapagliflozin alone with respect to reduction in % liver fat at the end of 12 weeks of double-blind treatment. Treatment effect in liver fat reduction (%) was assessed using a mixed linear model with the change from baseline on logarithmic scale as response variable and the logarithm of the baseline value as covariate, treatment as fixed effect, and center as random effect. The treatment effect was then back-transformed to original scale as Geometric mean ratio and presented as percentage change from baseline.
Time frame: 12 weeks
This study was conducted in 5 centers in Sweden between 20 January 2015 and 11 December 2015.
| Milestone | Epanova + Dapagliflozin | Dapagliflozin | Epanova | Placebo |
|---|---|---|---|---|
| Started | 22 | 21 | 20 | 21 |
| Completed | 20 | 20 | 15 | 20 |
| Not completed | 2 | 1 | 5 | 1 |
| Withdrew: Couldn't swallow ip; noncompliance | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 | 2 | 0 |
To evaluate the efficacy of the combination therapy (Epanova + Dapagliflozin) when compared to placebo with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded treatment. Treatment effect in liver fat reduction (%) was assessed using a mixed linear model with the change from baseline on logarithmic scale as response variable and the logarithm of the baseline value as covariate, treatment as fixed effect, and center as random effect. The treatment effect was then back-transformed to original scale as Geometric mean ratio and presented as percentage change from baseline.
| ratio of % liver fat | Epanova + Dapagliflozin | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo) | 0.79 (0.69 to 0.90) | 0.97 (0.90 to 1.04) |
To evaluate the relative efficacy of the combination of Epanova and dapagliflozin versus Epanova alone and dapagliflozin alone with respect to reduction in % liver fat at the end of 12 weeks of double-blind treatment. Treatment effect in liver fat reduction (%) was assessed using a mixed linear model with the change from baseline on logarithmic scale as response variable and the logarithm of the baseline value as covariate, treatment as fixed effect, and center as random effect. The treatment effect was then back-transformed to original scale as Geometric mean ratio and presented as percentage change from baseline.
| ratio of % liver fat | Epanova + Dapagliflozin | Dapagliflozin | Epanova |
|---|---|---|---|
| Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups) | 0.79 (0.69 to 0.90) | 0.87 (0.77 to 0.99) | 0.85 (0.78 to 0.92) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epanova + Dapagliflozin | — | 0/22 (0%) | 14/22 (63.6%) |
| Epanova | — | 0/20 (0%) | 12/20 (60%) |
| Dapagliflozin | — | 1/21 (4.8%) | 8/21 (38.1%) |
| Placebo | — | 1/21 (4.8%) | 7/21 (33.3%) |
| Event | Epanova + Dapagliflozin | Epanova | Dapagliflozin | Placebo |
|---|---|---|---|---|
| SepsisInfections and infestations | 0/22 | 0/20 | 0/21 | 1/21 |
| HydronephrosisRenal and urinary disorders | 0/22 | 0/20 | 1/21 | 0/21 |
| Event | Epanova + Dapagliflozin | Epanova | Dapagliflozin | Placebo |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/22 | 7/20 | 1/21 | 0/21 |
| DizzinessNervous system disorders | 2/22 | 1/20 | 5/21 | 1/21 |
| NauseaGastrointestinal disorders | 2/22 | 3/20 | 0/21 | 2/21 |
| Abdominal pain upperGastrointestinal disorders | 3/22 | 2/20 | 0/21 | 0/21 |
| NasopharyngitisInfections and infestations | 2/22 | 2/20 | 1/21 | 1/21 |
| ConstipationGastrointestinal disorders | 0/22 | 1/20 | 2/21 | 1/21 |
| HeadacheNervous system disorders | 1/22 | 0/20 | 0/21 | 2/21 |
| PollakiuriaRenal and urinary disorders | 2/22 | 1/20 | 2/21 | 1/21 |
| Age, Continuous(Years) | Epanova + Dapagliflozin | Epanova | Dapagliflozin | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 65.0 ± 5.42 | 66.2 ± 5.94 | 65.0 ± 6.54 | 65.6 ± 6.10 | 65.5 ± 5.92 |
| Age, Customized(Participants) | Epanova + Dapagliflozin | Epanova | Dapagliflozin | Placebo | Total |
|---|---|---|---|---|---|
| <50 | 0 | 0 | 1 | 0 | 1 |
| >=50 - <65 | 9 | 6 | 6 | 6 | 27 |
| >=65 | 13 | 14 | 14 | 15 | 56 |
| Sex: Female, Male(Participants) | Epanova + Dapagliflozin | Epanova | Dapagliflozin | Placebo | Total |
|---|---|---|---|---|---|
| Female | 7 | 9 | 5 | 4 | 25 |
| Male | 15 | 11 | 16 | 17 | 59 |
| Race/Ethnicity, Customized(Participants) | Epanova + Dapagliflozin | Epanova | Dapagliflozin | Placebo | Total |
|---|---|---|---|---|---|
| Black Or African American | 1 | 0 | 1 | 0 | 2 |
| White | 21 | 20 | 20 | 21 | 82 |
The record gives a start of Jan 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Omega-3 carboxylic acid · Dapagliflozin
Non-alcoholic Fatty Liver Disease →